Quipt Announces the Passing of Board Member Eugene Ewing

3 years ago

CINCINNATI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

3 years ago

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET CELEBRATION,…

Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022

3 years ago

English and Chinese Sessions to be Held to Accommodate Multiple Time ZonesFOSTER CITY, Calif., SHANGHAI and HANGZHOU, China, Jan. 12,…

iSTAR Medical shows initial positive progress of US STAR-V trial for MINIject

3 years ago

For immediate release iSTAR Medical shows initial positive progress of US STAR-V trial for MINIject Pivotal trial of MINIject, STAR-V,…

Wesana Health Provides Strategic and Operational Updates

3 years ago

Wesana granted pre-IND meeting with FDA, currently set for March 11, 2022Wesana Clinics exhibited a record quarter of billings, new…

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

3 years ago

TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company…

Landmark ADMIRAL Study Publication with CareDx’s AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance

3 years ago

ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients AlloSure…

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

3 years ago

•  Enables expansion of PCN-101 clinical development to the U.S. •  atai plans to initiate clinical drug-drug interaction (DDI) study in…

TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

3 years ago

CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a…

COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

3 years ago

Booster dose of candidate vaccine, COVAXIN™ (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using…